^
Association details:
| Biomarker: | ALK rearrangement |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | retaspimycin (IPI-504) (HSP90 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer
Excerpt:
Responses were also seen in three (12%) of the 26 KRAS wild-type patients, in one (8%) of the 12 patients known to be ALK wild-type, and in two (67%) of the three patients with an ALK rearrangement…
DOI:
10.1200/JCO.2010.30.8338
Trial ID:
